Adjuvant-Loaded Spiky Gold Nanoparticles for Activation of Innate Immune Cells

JUTAEK NAM,1,2 SEJIN SON,1,2,3 and JAMES J. MOON1,2,4

1Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; 2Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; 3Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA; and 4Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA

(Received 25 February 2017; accepted 14 August 2017)

Associate Editor Michael R. King oversaw the review of this article.

Abstract

Introduction—Gold nanoparticles are versatile carriers for delivery of biomacromolecules. Here, we have developed spiky gold nanoparticles (SGNPs) that can efficiently deliver immunostimulatory agents.

Objectives—Our goal was to develop a platform technology for co-delivery of multiple adjuvant molecules for synergistic stimulation and maturation of innate immune cells.

Methods—SGNPs were synthesized by a seed-mediated, surfactant-free synthesis method and incorporated with polyinosinic-polycytidylic acid (pIC) and DNA oligonucleotide containing unmethylated CpG motif (CpG) by an electrostatic layer-by-layer approach. Adjuvant-loaded SGNP nano-complexes were examined for their biophysical and biochemical properties and studied for immune activation using bone marrow-derived dendritic cells (BMDCs).

Results—We have synthesized SGNPs with branched nano-spikes layered with pIC and/or CpG. Adjuvant-loaded SGNP nano-complexes promoted cellular uptake of the adjuvants. Importantly, we achieved spatio-temporal control over co-delivery of pIC and CpG via SGNPs, which produced synergistic enhancement in cytokine release (IL-6, TNF-α) and upregulation of co-stimulatory markers (CD40, CD80, CD86) in BMDCs, compared with pIC, CpG, or their admixtures.

Conclusion—SGNPs serve as a versatile delivery platform that allows flexible and on-demand cargo fabrication for strong activation of innate immune cells.

Keywords—Inorganic nanoparticle, Adjuvant, TLR agonist, Vaccine delivery.
ABBREVIATIONS

BMDC Bone-marrow derived dendritic cell
CLR C-type lectin receptor
CpG Oligonucleotide containing unmethylated CpG motif
DMSO Dimethyl sulfoxide
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide
GNC Gold nanoparticle
GPC Gel permeation chromatography
MDA5 Melanoma differentiation-associated gene 5
MelM Methyl imidazole
MetNHS Metoxy poly(ethylene)propionic acid N-hydroxysuccinimide
NIR Near-infrared
NLR NOD-like receptor
NP Nanoparticle
PAM P Pattern-associated molecular pattern
PEG Poly(ethylene)glycol
PEI Poly(ethyleneimine)
pIC Polynosinic-polycytidylic acid
PRR Pattern-recognition receptor
RIG-1 Retinoic-inducible gene-1
RLR Retinoic acid-inducible gene (RIG)-I-like receptor
SGNP Spiky gold nanoparticle
SGNP@PEI SGNP coated with PEI
SP-C SGNP nano-complex layered with CpG
SP-P SGNP nano-complex layered with pIC
SP-P/C SGNP nano-complex layered with pIC and CpG
SPR Surface plasmon resonance
TEM Transmission electron microscope
TLR Toll-like receptor

INTRODUCTION

Induction of robust immune response requires engagement and activation of the innate immune system with danger signals from an exogenous pathogenic source or an endogenous source from tissue damage or cellular stress.55 Danger signals are recognized by pattern-recognition receptors (PRRs), which include Toll-like receptors (TLRs), C-type lectin receptors (CLRs), Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), and NOD-like receptors (NLRs).58 PRRs can recognize conserved microbial molecular structures, termed pathogen-associated molecular patterns (PAMPs), and the interaction between PRRs and PAMPs triggers inflammatory responses.58 Pathogen recognition during infection involves simultaneous or sequential engagement of PRRs on innate immune cells by multiple PAMPs, which activate distinct or shared signaling pathways and induce immune stimulation in a synergistic manner.30,39,61 Synthetic molecules mimicking the structures and functions of PAMPs can serve as effective adjuvants for stimulation of the innate immune system. In particular, TLR agonists have been widely investigated as vaccine adjuvants.23,26,43,56 However, they typically require high doses for in vivo administration and immune activation, thus raising potential safety concerns, such as reactogenicity at the injection site.15,55

On the other hand, particulate carriers may improve the potency and delivery of adjuvants by enhancing their solubility, stability, tissue and cell targeting.21,37 Thus, particle-based delivery of adjuvants may limit dose-dependent injection site toxicity and allow for dose-sparing of immunostimulatory agents.13 Our goal in this study was to develop a nanoparticle (NP) platform that can induce activation of innate immune cells and to perform initial characterization studies. In particular, gold nanoparticles (GNP) are one of the most extensively investigated inorganic NPs for drug delivery applications because of their intrinsic biocompatibility, well-defined synthetic and surface chemistry for targeted and controlled delivery, and in vivo stability.14,17,21,36,38,60,64 Here, we have designed spiky GNPs (SGNPs) as a versatile platform for intracellular co-delivery of multiple adjuvant molecules. Exploiting the high surface area-to-volume ratio of SGNPs attributed to their unique elongated nanospikes, we have decorated their surfaces with TLR agonists and endowed them with immunostimulatory properties. We have achieved this by employing the electrostatic layer-by-layer assembly process10–12,51,68,69 with cationic polyelectrolytes that mediate charge interaction between anionic surfaces of SGNP and adjuvants. Specifically, we coated spiky surfaces of SGNPs with polynosinic-polycytidylic acid (pIC) and oligonucleotide containing unmethylated CpG motif (CpG), pIC is a TLR3 agonist based on a synthetic double-stranded viral RNA analogue that promotes activation of macrophages and dendritic cells, while CpG is a DNA oligonucleotide-based TLR9 agonist that promotes robust innate and adaptive immune responses.2,3,33,54,57,62,63,70 Notably, the combination of pIC and CpG has been demonstrated to induce synergistic immune activation.3,62,70

Our proof-of-concept studies presented here were performed with bone-marrow derived dendritic cells (BMDCs), a widely-used model for innate immune cells. Our results indicate that these adjuvant-SGNP nano-complexes can promote efficient cellular uptake of pIC.
and CpG by innate immune cells and mediate co-delivery of multiple adjuvant species to endolysosomal compartments, where TLR3 and TLR9 are expressed, in a spatio-temporally controlled manner. In particular, co-localized delivery of dual adjuvants mediated by SGNP nano-complexes induced potent, synergistic immune activation of BMDCs with much lower concentrations of adjuvants than free soluble adjuvants. Our studies described here suggest that the SGNP system offers a simple yet versatile synthetic platform for dose-sparing of adjuvants and co-delivery of multiple immunostimulatory ligands to innate immune cells.

MATERIALS AND METHODS

Reagents and Instruments

L-ascorbic acid was obtained from Fisher Chemical. Methoxy poly(ethylene glycol) propionic acid N-hydroxysuccinimide (MW 5000, Methoxy-PEG-NHS) was purchased from Nanocs. pIC (high molecular weight, 1.5–8 kb) was purchased from Invivogen, and CpG (CpG 1826) was obtained from Integrated DNA Technology. Other chemicals were obtained from Sigma-Aldrich, and all reagents were used as received.

Synthesis of Citrate-Stabilized GNPs

Five mM deionized (DI) water solution of HAuCl₄ (300 ml, 1.5 mmol) was boiled to reflux for 30 min, then 1.5 M sodium citrate tribasic dehydrate (3 ml, 4.5 mmol) was quickly added with vigorous stirring. The solution color changed from yellow to red within 5 min as gold ion was reduced to form GNPs. The mixture was boiled for 10 min and then cooled for 30 min at room temperature. The resulting citrate-stabilized GNPs were stored at 4 °C until further use.

Synthesis of SGNPs

SGNPs were prepared as described in the literature with slight modifications. Ten ml of the above citrate-stabilized seed GNPs were diluted in 300 ml DI water and sequentially mixed with 3 ml of HAuCl₄ (20 mM, 60 μmol), 300 μl of 1 M HCl, and 3 ml of AgNO₃ (3 mM, 9 μmol) with vigorous stirring. After stirring for 1 min, 3 ml of L-ascorbic acid (40 mM, 120 μmol) was added, which induced abrupt color change from red to greenish black in 10 s indicating the SGNP formation. Finally, 300 μl of poly(ethylene glycol) methyl ether thiol (MW 6000; 10 mM, 3 μmol) was added to quench the reaction and stabilize the SGNPs. The mixture was further stirred for another 2 h at room temperature and centrifuged at 3,000×g for 60 min to remove excess unreacted reagents. The pellet was re-dispersed in 1 ml DI water and passed through illustra NAP-10 column (GE healthcare life sciences) for further purification. The resulting SGNPs were stored at 4 °C until further use. For physicochemical characterization of SGNPs, TEM images, hydrodynamic size, and zeta potentials were obtained after dilution in DI water.

Synthesis of Poly(ethylene glycol)-Grated Polyethylenimine (PEG-PEI)

Methoxy-PEG-NHS (400 mg, 80 μmol) was dissolved in 4 ml dimethyl sulfoxide (DMSO) by sonication. Polyethylenimine (PEI, MW 25,000; 100 mg, 4 μmol) dissolved in 1 ml DMSO was added to the above methoxy-PEG-NHS solution in a dropwise manner to achieve the final stoichiometry of 1:20 (PEI:PEG). The mixture was reacted for 24 h at room temperature with vigorous stirring and then dialyzed 6 times against DI water using Amicon ultra 10 kDa MW cutoff centrifugal filters to remove unreacted methoxy-PEG-NHS. The purified PEG-PEI conjugate was stored at −20 °C until further use.

Preparation of Adjuvant-Loaded SGNPs

PEI and PEG-PEI were dissolved in phosphate buffered saline (PBS), and the pH was adjusted to 7.4. DI water suspension of SGNPs (10 nM, 100 μl) was rapidly mixed with 100 μl PBS solution of PEI (2 mg/ml) and incubated for 10 min at room temperature. Excess free PEI was removed by centrifugation at 3000×g for 10 min. The pellet was dispersed in 200 μl PBS and mixed with 200 μl PBS solution of pIC (100 μg) and CpG (100 μg), either separately or together as indicated in the result section. After 10 min, the mixture was added to 400 μl PBS solution of PEG-PEI at a varying weight ratio (0:1–20:1 = PEG-PEI:adjuvants) and further incubated for 10 min. The crude mixture was purified from unloaded free adjuvants and PEIs by 2 rounds of centrifugation at 3,000×g for 10 min, using PBS (0.01% tween 20) and DI water, respectively.
loaded SGNPs were dispersed in DI water for further characterizations using dynamic light scattering and zeta potential. To verify the loading of adjuvant-PEG-PEI complexes, TEM images were acquired after staining SGNP complexes with 2% uranyl acetate (Electron Microscopy Sciences). Loading efficiency was calculated by releasing adjuvant-PEG-PEI complexes from SGNPs with treatment of heparin sulfate (1 mg/ml), followed by GPC analysis. Specifically, SGNP complexes were diluted in PBS (0.01% tween 20, 1 mg/ml heparin) and sonicated for 1 min at 40% amplitude (Qsonica Q125) to facilitate heparin-mediated dissociation of adjuvants from SGNPs. Free adjuvant was separated from SGNPs by centrifugation at 10,000×g for 5 min and quantified by GPC equipped with TSKgel G3000SWxl column (7.8 mm ID × 300 mm, Tosoh Bioscience LLC).

**Fluorophore Labeling of pIC and CpG for Confocal Microscopy**

For fluorophore labeling, S′ phosphate group of pIC and CpG was crosslinked with ethylenediamine *via* the 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling reaction in methylimidazole (MeIm) buffer, which tethers primary amine to the S′ phosphate group.⁴²,⁴³ Amine-reactive fluorophore dyes were then conjugated to the resulting ethylenediamine-crosslinked pIC and CpG. For pIC conjugation, 1 ml DI water solution of pIC (2.5 mg) was mixed with 19 μl of EDC (1 mg/ml, 100 nmol) and 13 μl of ethylenediamine (1 μl/ml, 200 nmol), and the volume was brought up to 1.2 ml using DI water and 1 M MeIm buffer to conduct the coupling reaction in 0.1 M MeIm buffer (pH 7.4). After 2 h reaction at room temperature, the mixture was dialyzed three times using Amicon ultra 3 kDa MW cutoff centrifugal filters with buffer exchange to 0.1 M NaHCO₃ (pH 8.0). To 1 ml of the above solution, 10 μl of Alexa Fluor® 647 NHS Ester (10 mg/ml, Invitrogen) was added and reacted for 2 h at room temperature. The mixture was dialyzed three times, freeze-dried, and stored at −20 °C. For CpG conjugation, 2 mg of CpG, 30 μmol of EDC, 60 μmol of ethylenediamine were used for amine functionalization. Then 40 μl of Alexa Fluor® 488 NHS Ester (10 mg/ml, Invitrogen) was conjugated to CpG. Concentrations of fluorophore-tagged pIC (pIC-AF647) and CpG (CpG-AF488) were measured using GPC, and they were used at the same amount (100 μg) for loading on SGNPs.

**Preparation and Maintenance of Bone Marrow-Derived Dendritic Cells (BMDCs)**

BMDCs were prepared according to the literature.⁴¹ BMDCs were maintained in RPMI 1640 (Gibco) supplemented 10% fetal bovine serum (Corning), 1% penicillin–streptomycin (Gibco), 20 ng/ml granulocyte–macrophage colony-stimulating factor (GM-CSF, Genscript), and 50 μM beta-mercaptoethanol (β-ME, Gibco). For incubation with samples, BMDCs were treated in the medium without GM-CSF and β-ME to prevent their potential impact on BMDC activation and surface modification of SGNPs, respectively. BMDC isolation was performed in compliance with the animal study protocol reviewed and approved by the Institutional Animal Care and Use Committee at the University of Michigan.

**Visualization of Intracellular Distribution of pIC and CpG Using Confocal Microscopy**

BMDCs were grown onto 12 mm glass coverslips in 24 well plates at a density of 5 × 10⁵ cells/well and incubated overnight at 37 °C under 5% CO₂. BMDCs were then treated with SP-P/C, SP-P + SP-C (formulated using pIC-AF647 and CpG-AF488), pIC-AF647 + CpG-AF488. Equivalent concentrations of adjuvants were used at 1 μg/ml CpG-AF488 and 1.8 μg/ml pIC-AF647. After 24 h, cells were washed three times with serum-free media and further incubated with 2 μg/ml Hoechst 33258 and 100 nM Lyso Tracker Red DND-99 (Invitrogen) in serum-free media for 30 min to stain nuclei and lysosomes, respectively. Cells were washed three times using PBS and fixed with 4% formaldehyde in PBS. Coverslips were mounted on slide glass using Fluoroshield Mounting Medium with anti-fade agent (Abcam), and the samples were visualized using Nikon A1Rsi Confocal Microscope.

**Activation of BMDCs**

Immature BMDCs were plated at a density of 1 × 10⁵ cells/well in 96 well plates and incubated overnight at 37 °C under 5% CO₂. Cells were then incubated with SGNP complexes or free soluble adjuvants. Specifically, we used SP-P/C, SP-P, SP-C, SP-P + SP-C, pIC, CpG, or pIC + CpG with their concentrations at 1 μg/ml CpG and 1.8 μg/ml pIC or 0.1 μg/ml CpG and 0.18 μg/ml pIC for 2 h and 24 h incubation, respectively. Cell culture media were collected for cytokine analysis with IL-6 and TNF-α ELISA kits (R&D system).

**Flow Cytometric Analysis of BMDC Maturation Markers**

BMDCs were plated at a density of 5 × 10⁵ cells/well in 24 well plates and incubated overnight at 37 °C under 5% CO₂. Cells were treated with free adjuvants.
or SGNP complexes with the concentrations at 0.1 μg/ml CpG and 0.18 μg/ml pIC. After 24 h, cells were collected and washed with 1% bovine serum albumin (BSA) in PBS, followed by centrifugation at 2,000 x g for 5 min. The cell pellet was suspended in 1% BSA in PBS and incubated with CD16/32 FcR blocking antibody (0.5 μg, eBioscience) for 10 min at room temperature. Cells were then stained with fluorophore-conjugated antibodies against cell surface markers including FITC-CD80 (0.2 μg, BD Biosciences), PE-CD86 (0.1 μg, eBioscience), APC-CD40 (0.1 μg, eBioscience), and PECy7-CD11c (0.1 μg, BD Biosciences) for 30 min at room temperature. Cells were washed twice with 1% BSA in PBS and suspended in 1% BSA in PBS containing 2 μM DAPI. Cells were then analyzed by flow cytometric analysis for quantification of upregulation of surface maturation markers.

Statistical Analyses

All values are reported as mean ± SD For statistical comparison of multiple samples, data were analyzed by one-way ANOVA with post hoc Turkey HSD test using Graphpad Prism 6.07 software. p values less than 0.05 were considered statistically significant. The level of statistical significance was defined as *p < 0.05, **p < 0.01, ***p < 0.001.

RESULTS AND DISCUSSION

The Overall Schematic and Synthesis of SGNPs

Overall, we have developed SGNPs as a delivery platform for adjuvants by utilizing an electrostatic layer-by-layer assembly approach (Fig. 1a). pIC and CpG are oligonucleotide-based adjuvants with multiple negative charges in their repeating phosphate backbone units. Our approach exploits the anionic charges of naïve pIC and CpG for self-assembly, thereby avoiding other complex chemical and structural modifications that may harm their immunological activities.9,24,25,27 We employed cationic polyelectrolytes to mediate the electrostatic assembly between SGNPs and nucleic acid-based adjuvants. Branched PEI (MW 25,000) was used as a model polyelectrolyte since it can readily form strong electrostatic complexation with oligonucleotides due to its high cationic charge density.5,40 SGNPs were coated with a PEI layer through electrostatic attraction (SGNP@PEI), onto which pIC and/or CpG were further layered and complexed. We prepared the SGNP complexes with either single (SP-P and SP-C) or dual (SP-P/C) adjuvants, and the outer pIC and/or CpG layers were coated with PEG-grafted PEI (PEG-PEI) to protect the adjuvants from degradation as well as to enhance colloidal stability of the complexes.
For the synthesis of core SGNPs, we have adopted a surfactant-free, seed-mediated growth method\(^\text{20}\) in order to alleviate potential toxicity associated with surfactants typically employed during the conventional synthesis of GNPs. Specifically, citrate-stabilized GNPs were prepared following the citrate reduction method\(^\text{16}\) and utilized as the seed for synthesis of SGNPs (Fig. 1b). The branched structures were grown from the seed GNPs using AgNO\(_3\) and ascorbic acid as the structure-directing agent and reducing agent, respectively. Our “bare” SGNPs, which were likely adsorbed with small molecules, such as citrate and ascorbate, easily aggregated during the purification processes. Hence, we have improved their colloidal stability by partially passivating their surfaces with PEG methyl ether thiol. The reaction was carefully controlled using the minimum concentration of PEG needed to preserve the initial anionic surfaces for the subsequent electrostatic assembly with cationic poly-electrolytes while at the same time maintaining colloidal stability during purification.

The synthesis of SGNPs was monitored using TEM and UV–Vis absorption measurements. The seed GNPs initially had spherical shape and small size, which turned into larger anisotropic SGNPs with multiple branched nano-spike structures after the growth reaction (Fig. 1c). The effective diameter, deduced from the surface area of each particle with the

**FIGURE 2.** Characterization of adjuvant-loaded SGNPs. HD size (a) and zeta potential (b) of SGNP complexes incorporated with pIC (SP-P), CpG (SP-C), or pIC/CpG (SP-P/C). The number after the abbreviation of adjuvants denotes the weight ratio of PEG-PEI relative to adjuvants. The dashed line signifies the HD size of “bare” SGNPs (a) and zeta potential value of zero (b). Representative TEM images of SGNP complexes formulated at the PEG-PEI weight ratio of 2.5 (c). TEM images were taken after 2% uranyl acetate staining. Scale bars = 50 nm.
assumption of their spherical morphology, increased from 16.1 (± 2.2) nm for GNPs to 48.7 (± 9.4) nm for SGNPs (Fig. 1d). The size distribution of SGNPs was reasonably narrow without any apparent particles as small as the seed GNPs. This indicates that the growth was very efficient with uniform reaction on most seed GNPs. The growth of branched structures was accompanied by the appearance of new surface plasmon resonance modes. SGNPs showed an intense UV–Vis absorption peak at 780 nm, which was redshifted by ~260 nm from that of the seed GNPs (Fig. 1e). The redshifted absorption band is ascribed to the unique surface plasmon resonance (SPR) mode that is governed by the aspect ratio of branches, whereas the small absorbance band that remained at 520 nm is due to the spherical cores.

Synthesis and Characterization of Adjuvant-Loaded SGNP Nano-Complexes

SGNP complexes were prepared by coating “bare” SGNPs with PEI (termed SGNPs@PEI), followed by loading of pIC and CpG either separately or together and the final PEG-PEI treatment, resulting in nanocomplexes referred to as SP-P for pIC, SP-C for CpG, SP-P/C for pIC/CpG. The amounts of SGNP (1 pmol), PEI (200 µg), pIC and CpG (100 µg each) were fixed, while the amount of PEG-PEI was adjusted in a range of 0:1–20:1 weight ratio of PEG-PEI:adjuvants for all complexations. The number after the abbreviation of adjuvants denotes the weight ratio of PEG-PEI relative to adjuvants.

The complexation process was monitored by measuring their hydrodynamic (HD) size and zeta potential through the assembly processes (Figs. 2a, 2b). The HD size and zeta potential of the “bare” SGNPs were 50.6 (± 15.2) nm and −22.6 (± 7.7) mV, respectively. The HD size was well correlated to the actual size measured by TEM in Fig. 1d and indicated singly dispersed particles. The anionic zeta potential of SGNPs allowed for electrostatic assembly with cationic PEI. After coating SGNPs with PEI, the anionic surface charge was converted to 20.2 (± 7.5) mV, which facilitated electrostatic complexation with pIC and CpG. Complexation with pIC caused a large increase in HD size (>30 nm) for both SP-P and SP-P/C, suggesting flocculation due to strong inter-particle charge interaction between pIC and PEI (Fig. 2a). However, the final PEG-PEI treatment reversed the flocculation, reducing the HD size to a level similar to that of well-dispersed SGNPs, suggesting that the PEG layer reduced inter-particle interaction by providing steric barrier. In contrast, CpG complexation did not cause flocculation, and SP-C remained stable in size regardless of the PEG-PEI treatment. The HD size increased slightly with the addition of adjuvant(s) and the PEG-PEI layer.
Upon complexation with pIC and/or CpG, the positive charge of SGNP@PEI was dropped to the range of ±10 mV (Fig. 2b). The subsequent PEG-PEI coating restored the cationic surface charge, which stabilized SP-P and SP-P/C from flocculation. Their zeta potential gradually increased with higher weight ratio of PEG-PEI and reached a plateau at 5 for all complexes, indicating that complete PEG-PEI coating was achieved at the weight ratio of 2.5–5. To further verify successful complexation, SGNP complexes formulated with the PEG-PEI weight ratio 2.5 were negatively stained with 2% uranyl acetate and examined under TEM (Fig. 2c). The TEM images clearly showed a thin adjuvant-PEG-PEI complex layer surrounding SGNPs as a white shade. It is also noted that SGNP complexes were well separated individually. This confirms substantial loading and stable complexation of adjuvants using our layer-by-layer approach.

**Quantification Method for pIC and CpG**

We have developed a method for quantifying the amount and loading efficiencies of pIC and CpG on SGNPs. When measured by UV–Vis absorption, both pIC and CpG in free forms exhibited a strong concentration-dependent absorption peak at ~260 nm (Figs. 3a, 3c). In particular, pIC had two distinctive peaks at ~245 and ~265 nm, corresponding to inosinic and cytidylic strands, respectively. We further developed a method to identify pIC and CpG simultaneously in a mixture solution, which could not be achieved by the UV–Vis absorption measurement alone because of their overlapping spectra. For this, we exploited the large differences between the molecular weights of pIC and CpG; pIC used in our studies has 1500–8000 base pairs whereas CpG has only 20 single bases (5' – tccatgacgttcctgacgtt-3'), resulting in >100-fold higher molecular weight for pIC, compared with CpG. Gel permeation chromatography (GPC) was performed for size-based separation of pIC and CpG, while the concentration was determined by measuring the absorbance at 260 nm (Figs. 3b, 3d). Differences in the elution time were large enough to identify pIC at ~7.7 min and CpG ~13.8 min, respectively, without any cross talk. pIC exhibited additional small peaks at ~15.7 min, probably due to residual amount of impu-
rities. However, their peak intensity was negligible, accounting for just ~3% of all peaks, and the peak position did not overlap with that of CpG. The integrated peak areas were linearly proportional to the concentrations of pIC and CpG with the coefficient of determination higher than 0.9999. Together with the UV–Vis absorbance-based concentration measurement, our GPC-based method allows for accurate identification and quantification of pIC and CpG simultaneously from their mixture solution.

**Determination of Adjuvant Loading on SGNP Nano-Complexes**

Adjuvant loading was confirmed using the UV–Vis absorbance and GPC methods as described above. As-prepared adjuvant-SGNP complexes showed an increased absorption peak at ~260 nm, compared with “bare” SGNPs and SGNP@PEI due to the presence of adjuvants (Fig. 4, the first column, boxed area). We note that uncomplexed free adjuvants were removed from SGNP complexes by centrifugation (3000 × g) and washing. SP-P/C showed a larger increase in their absorption peak at ~260 nm, compared with SP-P and SP-C, due to the loading of the dual adjuvants. The adjuvant loading efficiency was also dependent on the weight ratio of PEG-PEI, indicating that PEG-PEI contributed to the complexation. On the other hand, there were no noticeable changes in the absorption peak of the core SGNPs at ~780 nm, suggesting that the adjuvant complexation process did not directly affect the physicochemical properties of the base SGNPs.

For more quantitative assessment of adjuvant loading efficiency, we released surface-adsorbed pIC and CpG from SGNPs by heparin sulfate treatment and sonication. The increased absorption peaks that resulted from adjuvant loading completely disappeared after this heparin treatment, confirming complete release of adjuvants from SGNPs (Fig. 4, the second column, boxed area). The sonication step facilitated heparin-mediated adjuvant dissociation from SGNPs not only by physically disturbing the complexation but also by mildly heating the solution, thereby deforming the unstable branched structures and causing slight blue-shift of the SGNP absorption peaks. The released adjuvants were separated from SGNPs and quantified using the GPC-based quantification developed above (Fig. 4, the third column). SP-P and SC-C showed intense peaks corresponding to pIC and CpG, respectively (Figs. 4a, 4b, the third column), while SP-P/C showed two clearly separated peaks, each corresponding to pIC and CpG (Fig. 4c, third column). The peak positions of pIC and CpG released from SGNP complexes were identical to those of free adjuvants in Fig. 3, indicating that the complexation and heparin-mediated dissociation did not compromise the structural integrity of the adjuvants. “Bare” SGNPs and SGNP@PEI did not exhibit noticeable peaks in the elution time range, confirming the indicated peaks are wholly from adjuvants released from SGNP complexes.

The loading efficiency was obtained for pIC and CpG by calculating their concentrations based on the standard curve of peak area vs. concentration shown in Fig. 3. For SP-P, the loading efficiency of pIC was generally increased with the weight ratio of PEG-PEI,
reaching a plateau at 5. The only exception was found at the ratio of 1.3, at which PEG-PEI seemed to disturb the complexation (Fig. 4a, the forth column). For SP-C, the loading efficiency of CpG was unaffected or only marginally increased with PEG-PEI at the weight ratio of 1.3–5 and gradually decreased thereafter at higher ratio (Fig. 4b, forth column). In contrast, efficient co-loading of pIC and CpG on SP-P/C required the PEG-PEI treatment; there was almost no adjuvant loading without the PEG-PEI (Fig. 4c, forth column). With the PEG-PEI treatment at various ratios, the pIC loading efficiency was generally maintained at a substantial level, and its maximum loading efficiency was ~60% at the weight ratio of 5. On the other hand, the
DNA rather than linearized DNA. CpG may also affect the complexation strength as PEG-PEI possesses thousands of anionic charges per molecule, thus mediating strong complexation with PEG-PEI. The structure of adjuvants may also affect the complexation strength as PEG-PEI is known to preferentially complex with supercoiled DNA rather than linearized DNA. The outer PEG-PEI layer may also improve the in vivo stability of adjuvant-SGNP complexes by forming compact oligonucleotide condensates, while posing negligible cytotoxicity both in vitro and in vivo. Based on these results, the PEG-PEI weight ratio of 2.5 was used to prepare SP-P, SP-C, and SP-P/C complexes for subsequent studies since it achieved complete passivation with reasonable loading of both pIC and CpG.

**Intracellular Distribution of Adjuvants**

We monitored intracellular distribution of adjuvants either as a free form or after complexation with SGNPs by utilizing pIC and CpG labeled with Alexa Fluor® 647 and Alexa Fluor® 488, respectively (Fig. 5, as detailed in the Materials and Method section). The fluorophore-conjugated adjuvants were complexed with SGNPs as described above. The cell experiments were conducted using bone marrow-derived dendritic cells (BMDCs) to study the effects of adjuvants and their SGNP complexes on innate immune responses. BMDCs were incubated with pIC + CpG (free adjuvant combination), SP-P + SP-C (admixture of single SGNP complex), or SP-P/C (combinational SGNP complex) with equivalent concentrations of adjuvants at 1 μg/ml CpG and 1.8 μg/ml pIC. After 24 h, cells were stained for nuclei and lysosomes, fixed with 4% formaldehyde, and visualized with confocal microscopy. Free pIC + CpG exhibited only dim intracellular fluorescence (Fig. 5, first row), whereas SGNP complexes (SP-P + SP-C and SP-P/C) showed much brighter fluorescence, indicating that the complexation promoted cellular uptake of the adjuvants (Fig. 5, second and third row). This may be attributed to the positive surface charge of SGNP complexes, which allows favorable adsorption on negatively charged cellular membrane and facilitates subsequent cellular uptake. The nano-spike structures of SGNPs may also play a role by increasing the contact area with cellular membrane and promoting particle uptake via phagocytosis.

Although the extent of cellular uptake was similar for BMDCs treated with either SP-P + SP-C or SP-P/C, they showed a stark difference in intracellular distribution of adjuvants. Following the SP-P + SP-C co-treatment, pIC and CpG were distributed separately with limited co-localization, whereas significant overlap was observed in BMDCs treated with SP-P/C (Fig. 5, forth and fifth columns). We also examined localization of adjuvants in endolysosomes (Fig. 5, last two columns). Free pIC + CpG were found in endolysosomes, whereas SGNP complexes showed endolysosomal co-localization of the adjuvants as well as a portion of adjuvants localized in the cytosol with substantial fluorescence signal from pIC found in the cytosol for SP-P + SP-C and SP-P/C. The cytosolic localization may have resulted from the buffering capacity of PEI, which is known to mediate endosomal escape and cytosolic drug delivery by inducing swelling and rupturing of endolysosomes. Overall, these results demonstrate that adjuvant-loaded SGNP complexes can achieve spatio-temporal control over the combinational adjuvant delivery while enabling cytosolic delivery of adjuvants.

**Activation and Maturation of BMDCs**

We studied activation and maturation of BMDCs after incubation of BMDCs with free adjuvants or SGNP complexes, followed by analyses of cytokine release and surface marker expression. SGNP complexes containing dual adjuvants (SP-P/C) were compared with single adjuvant complexes treated either separately (SP-P or SP-C) or as an admixture (SP-P + SP-C). Free adjuvants (pIC, CpG, and pIC + CpG) were also used as control samples for the SGNP complexes. To examine BMDC activation, the samples were incubated with BMDCs for 2 h at concentrations of 1 μg/ml CpG and 1.8 μg/ml pIC, and the release of pro-inflammatory cytokines (IL-6 and TNF-α) was measured after 24 h (Fig. 6a). We found that CpG triggered substantial cytokine release, either as a free form or after complexation with SGNPs. In contrast, cytokine release was hardly detected with either form of pIC, indicating sub-optimal concentration of pIC for immune activation. BMDCs incubated with free pIC + CpG showed slightly higher cytokine levels than those exposed to free CpG, but the increase was only marginal. SP-P + SP-C did not further increase cytokine release over SP-C. In contrast, SP-P/C significantly increased release of IL-6 and TNF-α, compared with any of the treatment groups. We did not detect any cytokine release from
BMDCs incubated with plain SGNPs without any adjuvants (data not shown). Overall, these results suggest synergistic BMDC activation by SP-P/C-mediated co-delivery and potentiation of pIC and CpG. It is also noted that SP-C or SP-P + SP-C induced slightly higher levels of cytokine release than the respective free adjuvant samples, probably by enhancing cellular uptake as demonstrated in Fig. 5.

Next BMDC activation was further tested at tenfold lower sample concentrations (0.1 µg/ml CpG and 0.18 µg/ml pIC) (Fig. 6b). Our aim in this study was to validate the synergistic effect of SP-P/C at this low adjuvant concentration by minimizing the concentration-dependent diffusional overlap of separate adjuvants. Indeed, release of IL-6 and TNF-α were generally reduced by ~ tenfold due to the low adjuvant concentrations. However, SP-P/C treatment triggered robust release of IL-6 and TNF-α, with even greater relative differences from other control groups than those observed at higher adjuvant concentration (Fig. 6a). BMDC activation was accompanied by upregulation of co-stimulatory markers, including CD40, CD80, and CD86 (Fig. 7). Consistent with what we observed in the cytokine release assay, SP-P/C increased expression of co-stimulatory markers compared with other control samples (with the exception of free CpG).

Overall, these results demonstrate that SP-P/C can mediate spatio-temporally concerted delivery of combinatorial adjuvants, thereby promoting synergistic stimulation and maturation of innate immune cells. Our results showed that CpG induced immune stimulation of BMDCs whereas only negligible stimulation was found for pIC at the concentration range tested (0.1–1 µg/ml for CpG and 0.18–1.8 µg/ml for pIC), indicating sub-optimal concentration of pIC for immune activation by itself (Fig. 6) 34,46,62 However, when they were co-formulated on SGNPs, pIC greatly enhanced the immunostimulatory effect of CpG (Figs. 6, 7). Previous reports have shown synergistic immune stimulation by the combination of free pIC and CpG, but high concentration of pIC (>10 µg/ml) was required. 34,34,62,70 Compared with previous studies, our SP-P/C achieved increased immunostimulatory efficacy at much lower concentration of pIC. We speculate that such synergistic immune activation is attributed to SGNP-mediated co-delivery of pIC and CpG to the same cellular compartments (Fig. 5). In contrast, when the adjuvants were co-treated as an admixture either in free pIC + CpG form or SP-C + SP-P nano-complexes, the adjuvants were distributed separately with limited cellular co-localization due to poor spatial and temporal coordination of their uptake, leading to decreased cytokine release and maturation of BMDCs (Figs. 5, 6, 7). In addition to endosomal TLR3 and TLR9 (i.e. the canonical receptors for pIC and CpG, respectively), pIC is known to be detected by cytosolic dsRNA pattern recognition receptors, such as retinoic-inducible gene-1 (RIG-1) and melanoma differentiation-associated gene 5 (MDA5), which are RNA helicases that detect viral RNA species in the cytoplasm and induce type I interferon for viral clearance. 28,29,66 Thus, SGNP-mediated adjuvant delivery may trigger activation of multiple receptors, potentially broadening the breadth and strength of innate immune responses. We are currently working to delineate the mechanism underlying the adjuvant-receptor interactions and how sub-cellular localization of adjuvant(s) mediated by SGNPs vs. plain spherical gold nanoparticles affects innate and adaptive immune responses. In addition, SGNPs with strong near-infrared (NIR) SPR characteristics may be employed in NIR-based imaging and therapy. 19,32 potentially providing a versatile platform for theranostic applications in vaccines and immunotherapies.

**CONCLUSIONS**

In this study, we have developed SGNPs as a platform for efficient intracellular delivery of immunostimulatory agents. We prepared SGNPs by a seed-mediated, surfactant-free synthesis method, followed by surface-decoration with pIC/CpG molecules assembled via a layer-by-layer approach. As pIC and CpG are synthetic analogues of PAMPs, SGNPs complexed with pIC and/or CpG mimic certain aspects of immune activation by microbes. We have demonstrated that the combinatorial SP-P/C can co-deliver both adjuvants into BMDCs in a spatio-temporally concerted manner, leading to synergistic enhancement in immune stimulation and allowing for dose-sparing of adjuvants, whereas free soluble adjuvants or admixture of individually loaded adjuvant-SGNPs failed to achieve simultaneous, concerted delivery of adjuvants to the same sub-cellular compartments. In summary, SGNPs serve as a versatile delivery platform that allows flexible and on-demand cargo fabrication for strong activation of innate immune cells.

**ACKNOWLEDGMENTS**

This work was supported in part by NIH R01-AI127070, NIH R01-EB022563, NIH R01-CA210273, MTRAC for Life Sciences Hub, Emerald Foundation, and University of Michigan Comprehensive Cancer Center’s Forbes Institute for Cancer Discovery. J.J.M.
is a Young Investigator supported by the Melanoma Research Alliance (348774), NSF CAREER Award (1553831), DoD/CDMRP Peer Reviewed Cancer Research Program (W81XWH-16-1-0369), and Emerald (1553831), DoD/CDMRP Peer Reviewed Cancer Research Alliance (348774), NSF CAREER Award.

CONFLICT OF INTEREST

Jutaek Nam, Sejin Son, and James J. Moon declare no conflicts of interest.

ETHICAL STANDARDS

No animal or human studies were performed in this work.

REFERENCES

27. Kariko, K., and D. Weissman. Naturally occurring nucleoside modifications suppress the immunostimulatory


